Level C· Early human research exploring benefitsProspective StudyPubMed

Next Generation Bone Marrow Adiposity Researchers: Report From the 1 st BMAS Summer School 2021.

Labella R., Little-Letsinger S., Avilkina V., Sarkis R., Tencerova M., Vlug A.

Prospective Study, published in Front Endocrinol (Lausanne) (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Endocrinol (Lausanne) (2022)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
35498418
DOI
10.3389/fendo.2022.879588

Abstract (original English)

The first International Summer School on Bone Marrow Adiposity was organized by members of Bone Marrow Adiposity Society and held virtually on September 6-8 2021. The goal of this meeting was to bring together young scientists interested in learning about bone marrow adipose tissue biology and pathology. Fifty-two researchers from different backgrounds and fields, ranging from bone physiopathology to adipose tissue biology and hematology, participated in the summer school. The meeting featured three keynote lectures on the fundamentals of bone marrow adiposity, three scientific workshops on technical considerations in studying bone marrow adiposity, and six motivational and career development lectures, spanning from scientific writing to academic career progression. Moreover, twenty-one participants presented their work in the form of posters. In this report we highlight key moments and lessons learned from the event.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdiposityBone MarrowHumansObesitySchoolsSeasons

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.